Showing results (1-10 of 429) with videos related to
Sort By:
Pageof 43
The Journal of Steroid Biochemistry and Molecular Biology|April 30, 2005
Are aromatase inhibitors superior to antiestrogens?Anthony Howell, Aman BuzdarThe Surgical Clinics of North America|July 24, 2003
The current status of aromatase inhibitors in the management of breast cancerMichael Baum, Aman BuzdarThe Lancet. Oncology|December 18, 2007
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial, John F Forbes, Jack Cuzick, et al.The Lancet. Oncology|November 20, 2010
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialJack Cuzick, Ivana Sestak, Michael Baum, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trialAlistair Ring, Ivana Sestak, Michael Baum, et al.Clinical Breast Cancer|May 21, 2003
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trialAman BuzdarJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC studyMitch Dowsett, Jack Cuzick, Christopher Wale, et al.The Oncologist|January 6, 2005
How rapidly do oncologists respond to clinical trial data?Aman Buzdar, Cynthia MacahiligAmerican Journal of Obstetrics and Gynecology|November 21, 2008
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trialSean R Duffy, Wolfgang Distler, Anthony Howell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2015
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast CancerMitch Dowsett, Ivana Sestak, Richard Buus, et al.Pageof 43